Abstract
We have previously reported that U50,488 [(trans-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]benzeneacetamide] enantiomers contribute to visceral antinociception by a nonopioid receptor-mediated blockade of sodium currents in colon sensory neurons. The present experiments were undertaken to examine the effect of arylacetamide κ-opioid receptor agonists (κ-ORAs) U50,488 and EMD 61,753 [(N-methyl-N-[1S)-1-phenyl)-2-(13S))-3-hydroxypyrrolidine-1-yl)-ethyl]-2,2-diphenylacetamide HCl] on tetrodotoxin-sensitive (TTX-S) and -resistant (TTX-R) sodium currents, and the mechanism of their sodium channel-blocking actions. Whole cell patch-clamp experiments were performed on colon sensory neurons from the S1 dorsal root ganglion identified by content of retrograde tracer 1.1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine metanesulfonate. The concentration-response curves of U50,488 and EMD 61,753, for tonic inhibition of total, TTX-S, and TTX-R sodium currents were similar (EC50 values for U50,488 and EMD 61,753 were 8.4 ± 1.69 and 1.2 ± 1.78 μM, respectively). In contrast, the peptide κ-ORA dynorphin was without effect in these experiments. U50,488 (10 μM) shifted the voltage dependence of steady-state inactivation curves for total, TTX-S, and TTX-R currents to more negative potentials. Inhibition was present at holding potentials of –100 to –20 mV. After the tonic block elicited by 10 μM U50,488, repetitive stimulation with 5-ms depolarizing pulses at a frequency of 3 Hz further enhanced the inhibition of total, TTX-R, and TTX-S currents by 43.8 ± 4.9, 46.2 ± 4.9, and 40 ± 3.2%, respectively. These results demonstrate that arylacetamide κ-ORAs nonselectively inhibit voltage-evoked sodium currents in a manner similar to local anesthetics, by enhancing closed-state inactivation and induction of use-dependent block.
Footnotes
-
This study was supported by NS 19912 and NS 35790.
-
DOI: 10.1124/jpet.103.052829.
-
ABBREVIATIONS: U50,488, (trans)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]benzeneacetamide; EMD 61,753, (N-methyl-N-[(1S)-1-phenyl)-2-(13S))-3-hydroxypyrrolidine-1-yl)-ethyl]-2,2-diphenylacetamide HCl; ORA, opioid receptor agonist; KOR, κ-opioid receptor; TTX, tetrodotoxin; DRG, dorsal root ganglion; VASC, voltage-activated sodium current; TTX-S, tetrodotoxin-sensitive; TTX-R, tetrodotoxin-resistant.
- Received April 9, 2003.
- Accepted June 16, 2003.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|